Related Experiment Video
Updated: May 15, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
Diabetes-related adduct formation and retinopathy
Alan W Stitt1, Timothy M Curtis
1Centre for Vision and Vascular Science, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA Northern Ireland UK.
Abstract:
The pathogenesis of diabetic retinopathy is complex, reflecting the array of systemic and tissue-specific metabolic abnormalities. A range of pathogenic pathways are directly linked to hyperglycaemia and dyslipidaemia, and the retina appears to be exquisitely sensitive to damage. Establishing the biochemical and molecular basis for this pathology remains an important research focus. This review concentrates on the formation of a range of protein adducts that form after exposure to modifying intermediates known to be elevated during diabetes. These so-called advanced glycation end products (AGEs) and advanced lipoxidation end products (ALEs) are thought to play an important role in the initiation and progression of diabetic retinopathy, and mechanisms leading to dysfunction and death of various retinal cells are becoming understood. Perspective is provided on AGE/ALE formation in the retina and the impact that such adducts have on retinal cell function. There will be emphasis placed on the role of the receptor for AGEs and how this may modulate retinal pathology, especially in relation to oxidative stress and inflammation. The review will conclude by discussion of strategies to inhibit AGE/ALE formation or harmful receptor interactions in order to prevent disease progression from the point of diabetes diagnosis to sight-threatening proliferative diabetic retinopathy and diabetic macular oedema.
Insights
Diabetic retinopathy is driven by advanced glycation and lipoxidation end products (AGEs/ALEs) damaging retinal cells. Inhibiting AGE/ALE formation or receptor interactions may prevent vision loss in diabetes.
Area of Science:
- Ophthalmology
- Endocrinology
- Biochemistry
Background:
- Diabetic retinopathy pathogenesis involves complex metabolic abnormalities, with hyperglycemia and dyslipidemia damaging the retina.
- The retina is highly sensitive to metabolic damage, necessitating research into its biochemical and molecular basis.
- Advanced glycation end products (AGEs) and advanced lipoxidation end products (ALEs) are implicated in diabetic retinopathy progression.
Purpose of the Study:
- To review the formation and impact of AGEs and ALEs on retinal cells in diabetic retinopathy.
- To explore the role of the receptor for AGEs (RAGE) in modulating retinal pathology, including oxidative stress and inflammation.
- To discuss strategies for inhibiting AGE/ALE formation and receptor interactions to prevent diabetic retinopathy progression.
Main Methods:
- Review of existing literature on AGE/ALE formation and their role in diabetic retinopathy.
- Analysis of mechanisms underlying retinal cell dysfunction and death due to AGEs/ALEs.
- Discussion of the impact of RAGE signaling on retinal pathology.
Main Results:
- AGEs and ALEs are key contributors to diabetic retinopathy, causing retinal cell dysfunction and death.
- RAGE signaling exacerbates retinal pathology through oxidative stress and inflammation.
- Understanding these pathways provides targets for therapeutic intervention.
Conclusions:
- AGE/ALE formation and RAGE interactions are critical in diabetic retinopathy.
- Inhibiting these pathways offers potential strategies to prevent sight-threatening complications.
- Early intervention from diabetes diagnosis is crucial for managing disease progression.
Related Concept Videos
Diabetic Retinopathy
Diabetic Nephropathy
Complications of Diabetes Mellitus
Type II Diabetes II: Pathophysiology
Type I Diabetes III: Clinical Manifestations
Diabetic Neuropathy

